Abstract | BACKGROUND: METHODS: This was a multicenter study conducted at five sites within the US. The data were collected from 1 January 2004 to 31 January 2021. We conducted a retrospective analysis to identify PEComa patients with next-generation sequencing (NGS) data and compared outcomes based on mutations. RESULTS: No significant differences in survival were identified between TSC-1 and TSC-2 mutated PEComa or TSC-1/-2 versus other mutations. No significant difference was seen in progression-free survival (PFS) after first-line therapy between mTOR inhibition versus other systemic therapies. CONCLUSIONS: We were unable to detect differences in survival based on genomic alterations or PFS between mTOR inhibition versus other systemic therapies. Future studies should seek to identify other drivers of TSC-1/-2 silencing that could predict response to mTOR inhibition.
|
Authors | Lawrence Liu, Carina Dehner, Nikhil Grandhi, Yang Lyu, Dana C Borcherding, John S A Chrisinger, Xiao Zhang, Jingqin Luo, Yu Tao, Amanda Parkes, Nam Q Bui, Elizabeth J Davis, Mohammed M Milhem, Varun Monga, Mia Weiss, Brian Van Tine, Angela C Hirbe |
Journal | Genes
(Genes (Basel))
Vol. 13
Issue 11
(10 24 2022)
ISSN: 2073-4425 [Electronic] Switzerland |
PMID | 36360169
(Publication Type: Multicenter Study, Journal Article)
|
Chemical References |
- TOR Serine-Threonine Kinases
|
Topics |
- Female
- Humans
- Mutation
- Perivascular Epithelioid Cell Neoplasms
(genetics, pathology)
- Retrospective Studies
- TOR Serine-Threonine Kinases
(genetics)
|